Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)

尚未翻譯 尚未翻譯
类别 Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
連結 Registry of Trials

This article is not included in any systematic review

This article is part of the following publication threads:
  • DEDAS [Dose Escalation of Desmoteplase in Acute Ischemic Stroke] (3 documents)
Loading references information
The purpose of this study was to explore trends in safety and efficacy, and to find the optimal dose for the subsequent phase III trial. The decision to initiate the phase III trial will depend on both safety (incidence of symptomatic intracranial hemorrhage) and efficacy (reperfusion measured by MRI and correlating with clinical outcome) profiles. The safety (incidence of symptomatic intracranial haemorrhage) and efficacy (reperfusion measured by MRI and correlating with clinical outcome) profiles gained from this study were the basis of planning the phase III.
Epistemonikos ID: 65fd74bd268f80840a01a4a8d9003d4ab8b4c0cf
First added on: Apr 02, 2016